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Abstract
Purpose This study aims to test the hypothesis, in a single-
center retrospective analysis, that live birth rates are signifi-
cantly different when utilizing preimplantation genetic screen-
ing (PGS) compared to not utilizing PGS in frozen–thawed
embryo transfers in our patients that use eggs from young,
anonymous donors. The question therefore arises of whether
PGS is an appropriate intervention for donor egg cycles.
Methods Live birth rates per cycle and live birth rates per em-
bryo transferred after 398 frozen embryo transfer (FET) cycles
were examined frompatientswho elected to have PGS compared
to those who did not. Blastocysts derived from donor eggs
underwent trophectoderm biopsy and were tested for aneuploidy
using array comparative genomic hybridization (aCGH) or next-
generation sequencing (NGS), then vitrified for future use (test)
or were vitrified untested (control). Embryos were subsequently
warmed and transferred into a recipient or gestational carrier
uterus. Data was analyzed separately for single embryo transfer
(SET), double embryo transfer (DET), and for own recipient
uterus and gestational carrier (GC) uterus recipients.
Results Rates of implantation of embryos leading to a live
birth were significantly higher in the PGS groups transferring
two embryos (DET) compared to the no PGS group (GC, 72
vs. 56%; own uterus, 60 vs. 36%). The live birth implantation
rate in the own uterus group for SET was higher in the PGS
group compared to the control (58 vs. 36 %), and this almost
reached significance but the live birth implantation rate for the
SETGC group remained the same for both tested and untested
embryos. Live births per cycle were nominally higher in the
PGSGCDETand own uterus SETand DET groups compared
to the non-PGS embryo transfers. These differences almost
reached significance. The live birth rate per cycle in the SET
GC group was almost identical.
Conclusions Significant differences were noted only for DET;
however, benefits need to be balanced against risks associated
with multiple pregnancies. Results observed for SET need to
be confirmed on larger series and with randomized cohorts.
Keywords Aneuploidy . Preimplantation diagnosis for
aneuploidy (PGS) . IVF . Donor egg
Introduction
Approximately 12% of all in vitro fertilization (IVF) cycles in
the US are completed using donor eggs from young anony-
mous egg donors, which equated to over 20,000 cycles in
2013 [1]. Reasons for using donor eggs from young women
rather than autologous eggs during cycles of IVF are varied.
Capsule Outcome of donor egg FET cycles with and without PGS.
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They include advanced maternal age, premature ovarian fail-
ure, diminished ovarian reserve, multiple failed IVF cycles
using own eggs, oophorectomy, same-sex male couples, ma-
ternal single gene defects, and cancer treatment in the female
patient [1].
As aneuploidy frequency in human preimplantation em-
bryos increases with maternal age [2, 3], implantation and live
birth rates decrease [1] because most aneuploid embryos ei-
ther fail to implant [4] or miscarry and, rarely, are compatible
with life [5, 6]. National IVF live birth rates for embryo trans-
fers (ET) using fresh embryos compiled by the Centre for
Disease Control in 2013 from patients younger than 35 were
48% per ETcompared to patients aged 41–42 with a live birth
rate of only 16 % per ET [1]. While fresh embryo transfers
using donor eggs have resulted in high live birth rates without
PGS (live birth rate 77 %/ET 2012 SART published Oregon
Reproductive Medicine (ORM) data [7]), frozen ET live birth
rates in this group have been lower. Improvements in freezing
techniques over the last 10 years have led to better survival of
embryos and therefore higher pregnancy rates. National US
data [1] comparing fresh versus frozen ETs in the donor egg
recipient group showed that in 2003, fresh live birth rate/ET
was 51 % compared to frozen ET at 30 %. In 2013, the na-
tional fresh live birth rate/ET rate was 56 % compared to
40.5 % with frozen ET. The gap between fresh and frozen
embryo transfers has thus become less over this time period
from a 21% difference in 2003 to a 14.5% difference in 2013,
partly attributable to improved freezing methods.
PGS of blastocysts before transfer, it has been suggested,
can reduce the maternal age effect on implantation [8], signif-
icantly increase live birth rates, and reduce miscarriage risk in
IVF cycles when using autologous oocytes [9–16]. This area
is perhaps among the most contentious in reproductive med-
icine however with significant proponents and opponents on
both sides [17, 18]. Meta-analyses and randomized controlled
clinical trials have demonstrated the benefits of PGS for high-
risk groups (e.g., advanced maternal age, recurrent implanta-
tion failure); however, analyses and conclusions still attract
criticism [19, 20]. At the time of writing, the community
awaits the results of the Illumina STAR trial for PGS (trial
registration number NCT02268786).
To date, most attention has been on the high-risk referral
categories; however, many IVF/PGD practitioners have pro-
posed that all IVF embryos should be screened for aneuploidy
prior to transfer, including those from younger patients [21].
Although the percentage of aneuploid blastocysts from young
donors is low compared to older patients (25 % for donor eggs
vs. 60% for 41–43-year-old women, ORM unpublished data),
it is nonetheless a concern since most aneuploidies arise from
maternal meiotic errors in the eggs of younger women [22].
Sills et al. determined, using SNP technology, the parental
origin of aneuploidy using donor eggs [23], finding that
88 % of all the aneuploidies were attributable to maternal
errors. Despite this, egg donor cycles have historically been
the least likely group to be offered this screening.
To the best of our knowledge, there has only been one
study examining the use of PGS in frozen–thawed donor
egg derived embryos [24]. Their conclusion was that, al-
though their dataset was small, there was an increase (not
significant) in implantation rates and pregnancy rates in the
PGS group compared to the non-tested group. In the absence
of any statistical significance, however, results remain uncon-
vincing. A larger study is thus needed, as is stratifying patients
into Bown^ and Bgestational carrier^ uterus as well as double
versus single embryo transfers. In this study, we thus tested the
hypothesis that ongoing pregnancy and implantation rates in
frozen embryo transfer (FET) cycles are significantly different
in FET cycles utilizing PGS compared to FET cycles not uti-
lizing PGS in a single center.
Materials and methods
Ethical statement
All patients were consented for all procedures as part of rou-
tine care. Egg donors were all anonymous. Institutional review
board approval was obtained for review of patient charts and
laboratory data for this study. The University of Kent
Research and Ethics Committee also approved this study.
Overview
Blastocysts resulting from donor egg IVF cycles at the Oregon
Reproductive Medicine (ORM) clinic between January 2013
and December 2015 either elected to be tested for aneuploidy
by trophectoderm (TE) biopsy followed by PGS using aCGH
[25] or NGS [26] before cryopreservation; otherwise, their
embryos were cryopreserved without testing depending on
patient preference. All blastocysts subsequently transferred
in this retrospective observational study were at the day 5
stage when biopsied and frozen.
Recipient population and study design
Patients using donor eggs from Caucasian donors to create
embryos for their IVF cycle were included in this retrospective
analysis. The patients were divided into two main groups:
those using their own uterus and those using a gestational
carrier (GC) uterus for the embryo transfer. These groups were
further divided into those transferring a single embryo (SET)
and those transferring two embryos (double embryo transfer,
DET). The groups were then finally divided into those trans-
ferring apparently euploid embryos screened by PGS (study
group) and those transferring non-screened embryos (control
group).
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Donor stimulation, embryo culture, and blastocyst biopsy
Controlled ovarian stimulation protocols for these IVF
cycles were carried out as previously described [27]. On
completion of the retrieval procedure, oocytes were
placed in Quinns Advantage Fertilization Medium
(Origio, USA) supplemented with 5 % human serum
albumin (HSA) (Irvine Scientific, USA) under oil
(Ovoil, Vitrolife, USA), and ICSI or standard insemina-
tion performed 4 h after retrieval [28]. Once all eggs
had been either inseminated or injected, they were
returned to the incubator for overnight culture. All em-
bryos were moved to Quinns Advantage Cleavage
Medium (Sage, Origio, USA) supplemented with 10 %
HSA (Irvine Scientific) from days 1 to 3 and subse-
quently moved to Quinns Advantage Blastocyst
Medium (Sage, Origio, USA) supplemented with 10 %
HSA from days 3 to 6.
All embryos to be biopsied were hatched on day 3 post-
retrieval using a Hamilton Thorne Zilos™ laser with an
800-μm pulse then allowed to develop in culture media until
day 5 or 6 of development. Embryos were considered suitable
for biopsy on day 5 when at least 10 % of the TE was pro-
truding from the breach in the zona pellucida made on day 3.
All embryos that had not fully expanded by day 5 were cul-
tured until day 6 and then biopsied. Embryos were only
biopsied if there was a visible inner cell mass (ICM) and
multi-celled TE protruding from the zona pellucida.
Embryos that grew to an expanded blastocyst stage had three
to eight TE cells excised using a Hamilton Thorne Zilos™
laser with an 800-μm pulse. Biopsied embryos were then vit-
rified using Irvine vitrification media with DMSO (Irvine
Scientific, CA) on Cryotops (Kitazawa, Japan) and stored
for future use. Biopsied cells were sent to the Reprogenetics
Laboratory for analysis using NGS or aCGH.
DNA analysis
The biopsied cells were whole genome amplified
(WGA) using the Sureplex DNA Amplification System
(Bluegnome) according to the manufacturer’s protocol.
The WGA products were then processed for aneuploidy
analysis by NGS or aCGH. Testing by aCGH was proc-
essed using Bluegnome 24sure V3 protocol (Illumina,
Inc.) according to the manufacturer’s protocol. WGA
products were fluorescently labeled with Cy3 and Cy5
dyes and random primers and subsequently were pre-
pared to be hybridized to 24sure V3 array slides.
Aneuploidy data analysis was performed using
BlueFuse Multi Software. Testing by NGS was proc-
essed using Ion Torrent PGM (Ion Torrent) technology.
Libraries were prepared by fragmenting WGA products
with DNA concentrations of 100 ng using Ion Xpress
Plus Fragment Library Kit (Life Technologies). Library
fragments were selected at 200 bp using E-Gel
SizeSelect Gels (Life Technologies) and then were nor-
malized to 100 pM using an Ion Library Equalizer kit
(Life Technologies). Libraries were subsequently pooled
together into a mastermix and clonal amplified on the
Ion One Touch 2 system. The template was then loaded
into a 316 V2 chip (Life Technologies) and sequenced
at 200 bp. Aneuploidy data analysis was performed
using Ion Reporter software, using Low-Coverage
Whole-Gnome workflow.
Uterine preparation and blastocyst warming protocol
for embryo transfer
Embryo transfers of previously vitrified blastocyst stage em-
bryos were carried out in a medicated uterine preparation cy-
cle as described previously [29]. Embryos were warmed using
Irvine warming kits (Irvine Scientific, Irvine, CA) on the
morning of the scheduled embryo transfer and allowed to re-
expand in equilibrated drops of Embryoglue™ (Vitrolife) un-
der Ovoil™ (Vitrolife) until the time of transfer. Embryo
transfer was carried out using a Wallace Sureview Embryo
transfer catheter (CooperSurgical) under ultrasound guidance.
Patients rested for 45 min post-transfer.
Measured outcomes and statistical analysis
Measured outcomes were live birth rate per cycle and live
birth implantation rate (number of babies born per embryo
transferred). Any statistical differences in each of these param-
eters for each group were established using Fisher’s exact test
andMann-Whitney test on ranks where appropriate. Statistical
significance was determined at p <0.05 at the 95% confidence
level. The tested and non-tested groups had near identical
average egg donor age, and the number of embryos biopsied
in each group was not statistically significantly different
(Table 1).
During the study period, personnel in the laboratory all
remained constant, and there were no major changes to proto-
cols during the time period of the study.
Results
A total of 398 thaw cycles were included in the analysis. One
thaw cycle resulted in no transfer due to failure to survive of
the one available embryo. A total of 397 frozen ETs were
performed using blastocyst stage embryos generated from
eggs from anonymous donors. All embryos were classed as
of good morphological appearance (AA grade, Gardner scale)
[30] prior to cryopreservation. In the test (PGS) group, 435
known euploid embryos were transferred in 294 frozen ET
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cycles. In the control (no PGS) group, 103 embryos of un-
known ploidy status were transferred in 162 frozen ETcycles.
There was no difference in survival of embryos post-thaw
in both the PGS and control groups (96 % in the PGS group
and 97 % in the control group, p = 1.0 NS). No patients using
donor eggs during the time period of the study had a cycle
with all aneuploid embryos.
Results are summarized in Table 2. Live birth implantation
rates (number of babies born per embryo transferred) were
significantly higher in the PGS group in both the GC and
own uterus groups, but only after double embryo transfer
(DET) (72 vs. 56 % GC, 60 vs. 36 % own uterus; p-
values = 0.03 and 0.005, respectively). The live birth rates
per transfer cycle in the DET groups were nominally higher
in the PGS group compared to control group but not signifi-
cantly so (87 vs. 77%GC, 76 vs. 55% own uterus; p values =
0.2 and 0.08, respectively). Live birth implantation rates and
live births per cycle in the GC SET group were the same in the
PGS and own uterus group, but the control group was small
including only 20 cycles. Live birth implantation rates (58 vs.
36 %, p = 0.09) and live births per cycle (58 vs. 36 %, p =
0.09) were nominally higher with PGS versus control in the
SET own uterus group but not significantly.
Finally, live birth twinning rates were nominally higher
following PGS for DET cases (67 vs. 45 % for GC uterus,
p = 0.07 and 58 vs. 33 % for recipient own uterus, p = 0.1 in
Table 1 Comparison of donor age and numbers of embryos vitrified in test and control groups
Own uterus Gestational carrier uterus Total
PGS No PGS PGS No PGS PGS No PGS
Average donor age (range) 25.6 (20–33) 25.4 (19–32) 25 (21–30) 25.4 (21–30) 25.2 (20–33) 25.4 (19–32)
p value >0.5 not significant >0.5 not significant >0.5 not significant
Average embryos vitrified 6.9 6.4 7.9 7.6 7.5 7.0
p value >0.5 not significant >0.5 not significant >0.5 not significant
Results demonstrate highly similar (i.e., not significantly different) numbers
Table 2 Outcome measures: live births per cycle and live birth implantation rate (number of babies born per embryo transferred) in test (PGS) versus
control (no PGS) groups
Gestational carrier uterus Own recipient uterus



















95 20 100 26 58 25 41 33
Number of FETs 95 19 100 26 58 25 41 33
Number of
embryos transferred






13 (68 %) 93 (93 %) 22 (84 %) 37
(64 %)
10 (40 %) 34
(83 %)
20 (61 %)
p value 1.0 0.2 0.06 0.04




12 (60 %) 87 (87 %) 20 (77 %) 34
(58 %)
9 (36 %) 31
(76 %)
18 (55 %)







12 (63 %) 144
(72 %)
29 (56 %) 34
(58 %)
9 (36 %) 49
(60 %)
24 (36 %)
p value 1.0 0.03 0.09 0.005
Twinning
(rate/live birth)
0 0 58 (67 %) 9 (45 %) 0 0 18
(58 %)
6 (33 %)
p value 0.07 0.1 NS
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test and control groups, respectively) compared to zero mono-
zygotic twinning following SET in either the test or control
group.
Table 3 illustrates that 25 % of all donor egg derived
trophectoderm samples tested were aneuploid, 19 %
with a single aneuploidy and 5.7 % with more than
one chromosome involved. Table 3 breaks down the
errors by chromosome, with 4.6 % of embryos resulting
in a chromosomal aneuploidy commonly associated with
miscarriage or abnormal offspring (i.e., trisomies 13, 15,
16, 18, 21, 22, XY, and monosomy X). aCGH and NGS
methodologies resulted in similar overall aneuploidy
rates per embryo (24 % for aCGH vs. 26 % for NGS,
respectively, p > 0.05 not significant). Monosomies and
trisomies occurred at similar frequencies (overall and
per chromosome) with chromosome 16 and the sex
chromosomes most commonly aneuploid.
Discussion
Donor egg IVF cycles havemany variants. If the female donor
egg recipient is able to carry the pregnancy herself, the em-
bryos are transferred to her uterus. If, however, she has an
abnormal uterus or no uterus at all, the recipient may engage
a gestational carrier to gestate the pregnancy. Same-sex male
couples or single men can fertilize donor eggs with their own
sperm and transfer resulting embryos to a gestational carrier.
While the live birth rate of fresh donor egg embryos is high
overall, if the cases which used a gestational carrier are
Table 3 Results of aneuploidy
rates and specific chromosomes
affected for 3393 donor egg
derived blastocysts biopsied
between 2012 and 2015
Number of embryos biopsied 3393
Total with aneuploidy (% per embryo) 835 (25 %)
Number with complex aneuploidy (>1 chromosome
aneuploid) (% per embryo)
193 (5.7 %)
Number with single aneuploidy (% per embryo) 642 (19 %)
Single aneuploidy only:
















13 19 6 (0.2 %)a
14 13 6
15 22 16 (0.5 %)a
16 38 37 (1.1 %)a
17 6 3
18 9 4 (0.1 %)a
19 11 10
20 4 9
21 13 11 (0.3 %)a
22 24 15 (0.4 %)a
Sex chromosomes 35 (XO) (1 %)a 32 (0.9 %)a
Total number of embryos with most common aneuploidies
associated with implantation and subsequent miscarriage or
abnormal live birtha (% per embryo)
156 (4.6 %)
a Indicates the 4.6 % of embryos representing the most common trisomies associated with spontaneous abortion
and live birth
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separated out from the recipients who used their own uterus,
we find an even higher pregnancy rate in the donor egg ges-
tational carrier patients than when using a donor egg recipient
uterus from an infertile patient. This even higher pregnancy
rate when using a gestational carrier who has successfully
previously carried a baby to term could be attributable to the
elimination of unknown uterine factors that may contribute to
failure to achieve a successful pregnancy in patients who have
been infertile for long periods of time.
In this study, patients elected whether or not to test their
embryos by PGS before cryopreservation. The people who
elected not to test had the same prognosis as the patients
who did elect to test, i.e., all patients presenting in our anon-
ymous egg donor program had a high chance of conceiving
and had access to the same pool of young egg donors. Patients
committed to the testing process before the cycle started and
patients did not change their mind depending on how many
blastocysts developed. The reasons patients elected not to test
were financial, uncertainty about the biopsy process, and a
wish to leave the choosing of embryos up to chance.
Egg donor cycles have historically culminated in a transfer
of fresh, untested embryos to a recipient or gestational carrier
uterus or a freeze-all cycle for future use. With an average of
seven good quality blastocysts produced each donor egg cy-
cle, even if a fresh transfer is undertaken, there are usually
surplus embryos remaining to be cryopreserved for future
use [31]. Often an egg donor cycle cannot be synchronized
for a fresh embryo transfer with a recipient or gestational
carrier uterus for social or medical reasons and cryopreserva-
tion of the whole embryo cohort (Bfreeze all^) becomes nec-
essary [32, 33]. The findings of this study indicate that there
are possible benefits in implantation and ongoing pregnancy
rates through the use of PGS in FET donor egg cycles. The
question of whether FETcycles derived from donor eggs need
to include PGS in future should thus now be subject of larger
and ultimately randomized studies.
Single-center retrospective cohort studies such as this one
provide supportive evidence to justify future prospective co-
hort studies, multi-center meta-analyses, and ultimately ran-
domized controlled clinical trials (RCTs). For evidence-based
reproductive medicine, each has their value. RCTs remain the
gold standard, but in a field where individual operator skills
can have such a profound effect on IVF outcome, larger stud-
ies can mask effect of good (or bad) practice of individual
groups or centers. In this context, smaller single-center trials
have considerable value and may point to genuine efficacy of
clinical interventions. On the other hand, the absence of ran-
domization leaves an open question of whether any significant
differences observed represent selection bias, inadvertent or
otherwise. Moreover, different sizes of test and control groups
(in this case, control groups are much smaller than test groups)
mean that statistical analyses need to be viewed with a degree
of caution. RCTs are however expensive, time consuming,
and cannot be justified without sufficient published datasets
from retrospective analyses. In our opinion, the current study
justifies further work in this area, particularly with the in-
creased interest in IVF and PGS.
With all the above caveats in mind, the current study is
nonetheless the first to show significant differences as a result
of the use of PGS in patients who elected to have it as part of
their FET donor egg treatment cycle. Apparent improvements
were seen after double embryo transfer (DET), raising the
question of whether differences are only likely to be seen in
this context. Equally, as the IVF world in most countries
moves more in the direction of single embryo transfers
(SET) [34–36], attention will inevitably turn to means through
which the chances of implantation of that single embryo can
be maximized. In our SET GC group, there was no difference
in live births per cycle nor live birth implantation rates per
embryo between the PGS and no PGS embryos, and in the
SET group using a recipient uterus, there was a nominal in-
crease in those parameters when using PGS but not signifi-
cantly. Taking gestational carrier and own uterus cycles to-
gether, all measures favored the PGS cycles, but in the ab-
sence of statistical significance, the question remains open
about whether this represented a genuine difference. The
DET results suggest that, had sufficient numbers been ana-
lyzed, the numbers might have reached statistical significance
for SET also; however, this needs to be confirmed by further
studies. Elective single embryo transfer (SET) to reduce mul-
tiple pregnancy rates in IVF cycles is a primary goal of the
reproductivemedicine community [35]. SETs, however, result
in lower pregnancy rates per transfer and higher rates of com-
plete pregnancy loss (post-positive pregnancy test) compared
to double embryo transfer (DET). The benefit of transferring a
single embryo is the reduction in the number of twin pregnan-
cies because of the obstetric complications associated with
multiple births. In future studies, therefore, we would look
closely to ask whether the nominal differences seen for SET
in this study reach statistical significance in larger data sets.
Without randomization, the question also arises about
whether the statistical differences that were observed reflect
patient cohorts that inherently had differing aneuploidy rates.
Of course, we cannot completely rule this out. In these partic-
ular patient groups, however, patients had near identical egg
donor ages, the best known correlate for different aneuploidy
rates [2, 3, 8]. Equally, the couples who elected not to test had
the same prognosis as the patients who did elect to have PGS,
i.e., all patients presenting in our anonymous egg donor pro-
gram had a high chance of conceiving and had access to the
same pool of young egg donors. Patients committed to the
testing process before the cycle started and patients did not
change their mind depending on how many blastocysts devel-
oped. The reasons patients elected not to test were financial,
uncertainty about the biopsy process, and a wish to leave the
choosing of embryos up to chance. Whether these are
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confounding factors that might predispose to increased aneu-
ploidy or reduced pregnancy is questionable. In a study of 23
US clinics sending biopsies to a single reference laboratory
(Reprogenetics), Munne et al. showed that aneuploidy rates in
donor egg embryos vary between IVF clinics [37]. The per-
cent of aneuploid donor egg embryos per clinic ranged from
20 to 58 % with an average rate of 35 %. One possible expla-
nation for this is geographical variation in aneuploidy rates;
however, there is scant data supporting this hypothesis. A
more likely explanation is subtle differences in ovarian stim-
ulation and laboratory protocols might lead to marked differ-
ences in aneuploidy levels between centers. Such questions
are beyond the scope of this study and are not entirely relevant
in this case as this is a single-center study in which personnel
did not change and identical standard operating practices were
performed. Indeed, in our own experience, donor egg aneu-
ploidy rates are lower than the average shown in the Munne
study [26]. Nonetheless, we cannot rule out inadvertent, subtle
differences between treatments of test versus control groups,
however unlikely we believe it to be. It is perhaps not unrea-
sonable to suggest, however, that the centers with higher an-
euploidy rates in embryos derived from donor eggs might be
the ones that benefit most from PGS, should it ultimately
prove effective for this application.
Donor egg pregnancies, although at lower risk for miscar-
riage or offspring with chromosomal defects than pregnancies
from patients of advanced maternal age, are still at risk from
adverse pregnancy outcomes. The most common single aneu-
ploidies associated with miscarriage or congenitally affected
live births are trisomies 13, 15, 16, 18, 21, 22, XY, and mono-
somy X [38, 39]. In this retrospective analysis, 4.6 % of blas-
tocysts fall into this category (Table 3). Given that mono-
somies (other than monosomy X) are rarely, if ever, seen
among spontaneous abortions, we might expect these and oth-
er trisomies (e.g., trisomies 1 and 19) not to reach the stage of
a clinically recognized pregnancy, perhaps through failed im-
plantation. Others, however, such as the more common triso-
mies above, remain a significant concern for donor egg recip-
ients when using unscreened embryos for transfer, especially
since prenatal diagnosis is not routinely recommended for this
group. Other features also noteworthy from Table 3 include
monosomies and trisomies that occur with equal frequency
indicating that embryos are equally likely to survive to the
blastocyst stage whether they arise from a nullisomic or diso-
mic gamete. Moreover, the most common aneuploidies seen
in spontaneous abortions (monosomy X and trisomy 16) [40]
are the most common in this dataset, suggesting that some
patterns of chromosome-specific rates of aneuploidies are laid
down before implantation.
PGS costs around $4500 (including biopsy procedure plus
testing process) per cycle in addition to the IVF cycle costs.
The cost including medication of one FETcycle is also around
$4500. As 45 % of non-PGS embryos fail to implant and
result in a pregnancy compared to 22 % of PGS embryos, it
is more likely that a second or maybe third frozen embryo
transfer may be needed to achieve a successful outcome when
using untested embryos, therefore offsetting the initial cost of
embryo screening.
Aneuploidy is a condition that affects all age groups, even
women in their twenties [3]. While it has been suggested that
PGS is a valuable tool for improving outcome in patients of
advanced maternal age [8]; in the current study, we provide
preliminary evidence that the application of PGS may im-
prove IVF outcomes using younger oocytes from an egg do-
nation cycle. This research provides sufficient evidence for
increased research in this area, ultimately leading to prospec-
tive randomized clinical trials to address this issue further.
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